Skoulidis, F., Cuppens, K., Theelen, W. S., Zhou, C., Felip, E., Eom, J. S., Friedmann, J., Daniele, G., Veluswamy, R., Solomon, B. J., Moran, T., Silva, F. A. F. D., Vera, K., Mayo, M. C., Rahman, A., Li, S., Prizant, H., Stroud, C. R., Meyenberg, C., Sacher, A. G. (2026). First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic
                    <i>KRAS</i>
                    G12C+ non–small cell lung cancer (NSCLC): Results from the Krascendo-170 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8510